Children Affected by Rare Disease and Their Families Network

NCT ID: NCT04339465

Last Updated: 2022-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

687 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The project at hand will test two innovative forms of care (CARE-FAM and WEP-CARE) at 17 sites in 12 federal states of Germany. The goal is to improve the mental health and quality of life of children affected by rare diseases and their relatives in a sustainable manner. If successful, these interventions will be introduced into regular care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The central objective of the study at hand is to close the supply gap for families with children and adolescents affected by rare diseases. Two innovative forms of care (CARE-FAM and WEP-CARE) will be implemented and evaluated at the 18 participating study sites. Both interventions include psychological diagnostics, early detection and treatment of concomitant mental diseases. The study is a prospective, randomized controlled multicenter study (RCT) with a factorial design with four groups: CAREFAM (face to face), WEP-CARE (online), both interventions, control group (TAU = treatment as usual). Central psychosocial outcomes will be assessed at four time points (i.e., Baseline and after six, 12 and 18 months) from the perspectives of the parents, the affected child and the siblings (0 - 9 years only external assessment; from 10 years of age additional self-assessment) and the professionals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rare Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

The study is a prospective, randomized controlled multicenter study (RCT) with a factorial design with four groups: CAREFAM (face to face), WEP-CARE (online), both interventions, control group (TAU = treatment as usual).
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Investigators
Assessors are blind regarding the randomization (group affiliation) of the families.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CARE-FAM

The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).

Group Type EXPERIMENTAL

CARE-FAM

Intervention Type BEHAVIORAL

CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.

WEP-CARE

The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform. The 12 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.

Group Type EXPERIMENTAL

WEP-CARE

Intervention Type BEHAVIORAL

WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform

CARE-FAM + WEP-CARE

The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.

Group Type EXPERIMENTAL

CARE-FAM

Intervention Type BEHAVIORAL

CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.

WEP-CARE

Intervention Type BEHAVIORAL

WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform

Treatment as usual

The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CARE-FAM

CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.

Intervention Type BEHAVIORAL

WEP-CARE

WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Family with at least one child between 0 and 21 years with a rare disease or a suspected rare disease.
2. Consent to participate in the study.
3. Sufficient knowledge of the German language of parents and children.
4. Insured at the participating insurance companies.
Minimum Eligible Age

1 Day

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Techniker Krankenkasse

OTHER

Sponsor Role collaborator

BARMER

OTHER

Sponsor Role collaborator

DAK Gesundheit

OTHER

Sponsor Role collaborator

KKH Kaufmännische Krankenkasse

UNKNOWN

Sponsor Role collaborator

BKK Mobil Oil

INDUSTRY

Sponsor Role collaborator

Achse e.V.

UNKNOWN

Sponsor Role collaborator

University of Ulm

OTHER

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role collaborator

University Hospital Schleswig-Holstein

OTHER

Sponsor Role collaborator

University Medical Center Rostock

OTHER

Sponsor Role collaborator

University Hospital Muenster

OTHER

Sponsor Role collaborator

University Hospital, Essen

OTHER

Sponsor Role collaborator

Ruhr University of Bochum

OTHER

Sponsor Role collaborator

Universitätsklinikum Köln

OTHER

Sponsor Role collaborator

University of Göttingen

OTHER

Sponsor Role collaborator

Hannover Medical School

OTHER

Sponsor Role collaborator

Evangelisches Klinikum Bethel

UNKNOWN

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

DRK Kliniken Berlin Westend

UNKNOWN

Sponsor Role collaborator

Universitätsklinikum Leipzig

OTHER

Sponsor Role collaborator

University of Giessen

OTHER

Sponsor Role collaborator

University Hospital Freiburg

OTHER

Sponsor Role collaborator

Josefinum Augsburg

UNKNOWN

Sponsor Role collaborator

University Hospital Augsburg

OTHER

Sponsor Role collaborator

University Hospital, Saarland

OTHER

Sponsor Role collaborator

Jena University Hospital

OTHER

Sponsor Role collaborator

Leibniz Universität, Center for Health Economics Research Hannover

UNKNOWN

Sponsor Role collaborator

aQua-Institut

UNKNOWN

Sponsor Role collaborator

Silke Wiegand-Grefe, Prof. Dr.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Silke Wiegand-Grefe, Prof. Dr.

Prof. Dr.

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Center Klinikum Augsburg, Kinderklinik Augsburg, l. Klinik für Kinder- und Jugendliche

Augsburg, , Germany

Site Status

Medical Center DRK Kliniken Berlin Westend, Klinik für Kinder- und Jugendmedizin

Berlin, , Germany

Site Status

Medical Center Evangelisches Klinikum Bethel, Klinik für Kinder- und Jugendmedizin

Bielefeld, , Germany

Site Status

University Medical Center Ruhr-Universität Bochum, Klinik für Kinder- und Jugendmedizin

Bochum, , Germany

Site Status

University Medical Center Universitätsklinik Köln, Klinik für Kinder- und Jugendmedizin

Cologne, , Germany

Site Status

University Medical Center Universitätsklinikum Essen, Kinderklinik I, Neuropädiatrie

Essen, , Germany

Site Status

University Medical Center Universitätsklinikum Freiburg, Zentrum für Allgemeine Kinder- und Jugendmedizin, Klinik l

Freiburg im Breisgau, , Germany

Site Status

University Medical Center Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Kinderklinik, Abteilung für Kinderneurologie, Sozialpädiatrie u. Epileptologie

Giessen, , Germany

Site Status

University Medical Center Universitätsmedizin Göttingen, Klinik für Kinder- und Jugendmedizin

Göttingen, , Germany

Site Status

University Medical Center Universitätsklinikum Hamburg-Eppendorf, Klinik für Kinder- und Jugendmedizin

Hamburg, , Germany

Site Status

University Medical Center Medizinische Hochschule Hannover, Klinik für Pädiatrische Nieren-, Leber- und Stoffwechselerkrankungen

Hanover, , Germany

Site Status

University Medical Center Universitätsklinikum des Saarlandes, Homburg, Klinik für Allgemeine Pädiatrie und Neonatologie

Homburg, , Germany

Site Status

University Medical Center Universitätsklinik Jena, Klinik für Kinder- und Jugendmedizin

Jena, , Germany

Site Status

University Medical Center Universitätsmedizin Leipzig, Universitätskinderklinik

Leipzig, , Germany

Site Status

University Medical Center Charité-Universitätsmedizin Berlin, Klinik für Kinder- und Jugendmedizin

Mitte, , Germany

Site Status

University Medical Center Universitätsklinikum Münster, Klinik für Kinder- und Jugendmedizin

Münster, , Germany

Site Status

University Medical Center Universitätsmedizin Rostock, Kinder- und Jugendklinik

Rostock, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Boettcher J, Filter B, Denecke J, Hot A, Daubmann A, Zapf A, Wegscheider K, Zeidler J, von der Schulenburg JG, Bullinger M, Rassenhofer M, Schulte-Markwort M, Wiegand-Grefe S. Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design. BMC Fam Pract. 2020 Nov 20;21(1):239. doi: 10.1186/s12875-020-01312-9.

Reference Type DERIVED
PMID: 33218310 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1223-2871

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.